Skip to main content

Table 4 Published experience of systemic therapy in metastatic/locally advance SFT

From: Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience

 

Pts

RR with RECIST

RR with Choi

OS (mos)

PFS (mos)

Sunitinib (Stacchiotti)

31

6.4%

NR

16.0

6.0

Sorafenib (FSG)

5

0%

NR

19.7

NR

Antiangiogenic drugs (Levard)

10

0%

NR

NR

5.1

Temozolamide and Bevacizumab (Park)

14

NR

79%

NR

9.7

Dacarbazine (Stacchiotti)

8

37.5%

NR

NR

7.0

Anthracycline (Costantinidou)

17

5.8%

NR

14.6

4.2

Chemotherapy (Levard)

23

9%

NR

NR

5.2

Pazopanib (present study)

13

9%

46%

13.3

4.7

  1. (mos = months, NR = not reported, pts = number of patients, RR = response rate).